WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--GARDASIL® [Human Papillomavirus Quadrivalent] (Types 6, 11, 16, 18) Vaccine, Recombinant] prevented 91 percent of cases of persistent infection, low-grade cervical abnormalities, and pre-cancers, and external genital lesions caused by HPV types 6, 11, 16 and 18 compared with placebo in women aged 24 through 45, according to new data presented today at the 24th International Papillomavirus Conference (IPC) in Beijing, China
